This study will investigate the use of sertraline (Zoloft) to decrease alcohol consumption
and crime-related post-traumatic stress disorder in those individuals with both disorders.
This will be a 12-week, placebo-controlled, double-blind outpatient trial.
All subjects will receive cognitive behavioral therapy in addition to a placebo or
sertraline. Comprehensive evaluation will be done at study entry; treatment termination;
and 6, 9, and 12 months after study entry.
- Meets criteria for alcohol abuse or dependence and post-traumatic stress disorder.
- Laboratory tests for blood and urinalysis must be within normal limits.
- Must be clearly motivated to obtain benefit from treatment and keep appointments for
study visits and therapy sessions.
- Females who use an acceptable method of birth control, are sterilized, or are at
least 2 years post-menopausal.
- Have a diagnosis of schizophrenia, bipolar affective disorder, dissociative identity
disorder, eating disorder, substance dependence in the last 60 days.
- Currently suicidal.
- Medical reasons not to receive drug therapy.
- Allergy or hypersensitivity to selective serotonin inhibitor antidepressants.
- Significant hematological, endocrine, cardiovascular, renal, hepatic, neurological,
or gastrointestinal disease.
- Liver function test greater than 2 times the normal level
- Require ongoing therapy with another psychoactive drug during the study period.
- Females who are pregnant or lactating.